title: [Tyrosine kinase inhibitors for the treatment of papillary thyroid cancer].
abstract: Since 2005, different types of multitargeted tyrosine kinase inhibitors were used in clinical trials for the treatment of patients with advanced thyroid cancers. Experimental studies have demonstrated that tyrosine kinase inhibitors has both anti-proliferative and anti-angiogenic properties in vitro and in vivo, against thyroid cancer cells. Furthermore, several completed (or ongoing) studies have evaluated the long-term efficacy and tolerability of tyrosine kinase inhibitors in patients with papillary, follicular and medullary aggressive thyroid cancer. The results of the different studies showed good clinical responses and stabilization of the disease and suggested that tyrosine kinase inhibitors are a promising therapeutic option in patients with advanced thyroid cancer that is not responsive to traditional therapeutic strategies (such as radioiodine).
authors.affiliation: Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa, Italia.
authors.forename: U
authors.initials: U
authors.lastname: Politti
mesh_terms: D018276:Carcinoma, Medullary / Q000188:drug therapy; D002291:Carcinoma, Papillary / Q000188:drug therapy*; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D047428:Protein Kinase Inhibitors
keywords: Selumetinib; Sorafenib; Sunitinib; Thyroid cancer; Tyrosine kinase inhibitor; Vandetanib